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RESEARCH ARTICLE
The Cost-Effectiveness of Improving
Diabetes Care in U.S. Federally
Qualified Community Health Centers
Elbert S. Huang, Qi Zhang, Sydney E. S. Brown, Melinda L.
Drum, David O. Meltzer, and Marshall H. Chin
Objective. To estimate the incremental cost-effectiveness of improving diabetes care
with the Health Disparities Collaborative (HDC), a national collaborative quality im-
provement (QI) program conducted in community health centers (HCs).
Data Sources/Study Setting. Data regarding the impact of the Diabetes HDC pro-
gram came from a serial cross-sectional follow-up study (1998, 2000, 2002) of the pro-
gram in 17 Midwestern HCs. Data inputs for the simulation model of diabetes came
from the latest clinical trials and epidemiological studies.
Study Design. We conducted a societal cost-effectiveness analysis, incorporating data
from QI program evaluation into a Monte Carlo simulation model of diabetes.
Data Collection/Extraction Methods. Data on diabetes care processes and risk
factor levels were extracted from medical charts of randomly selected patients.
Principal Findings. From 1998 to 2002, multiple processes of care (e.g., glycosylated
hemoglobin testing [HbA1C] [71 ! 92 percent] and ACE inhibitor prescribing
[33 ! 55 percent]) and risk factor levels (e.g., 1998 mean HbA1C 8.53 percent, mean
difference 0.45 percent [95 percent confidence intervals  0.72,  0.17]) improved
significantly. With these improvements, the HDC was estimated to reduce the lifetime
incidence of blindness (17 ! 15 percent), end-stage renal disease (18 ! 15 percent),
and coronary artery disease (28 ! 24 percent). The average improvement in quality-
adjusted life year (QALY) was 0.35 and the incremental cost-effectiveness ratio was
$33,386/QALY.
Conclusions. During the first 4 years of the HDC, multiple improvements in diabetes
care were observed. If these improvements are maintained or enhanced over the life-
time of patients, the HDC program will be cost-effective for society based on tradition-
ally accepted thresholds.
Key Words. Quality improvement, cost-effectiveness analysis, safety net providers
Deficiencies in the quality of care of chronic conditions such as diabetes are
well recognized as a major public health problem (Committee on Quality of
Health Care in America 2001; McGlynn et al. 2003). Concerns regarding
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these deficiencies have led to significant public investment in quality im-
provement (QI) programs and related disease management programs (Flem-
ing et al. 2001; Casalino 2005). One of the longest-running national QI
programs is the Health Disparities Collaboratives (HDC) initiated in 1998 by
the Health Resources and Services Administration’s Bureau of Primary Health
Care (HRSA’s BPHC) in federally qualified community health centers (HCs).
This program began with a focus on improving the quality of diabetes care.
Short-term studies of the Diabetes HDC have shown that the program improved
processes of diabetes care after 1 year of implementation (Chin et al. 2004).
Long-term follow-up of the Diabetes HDC over 4 years has more recently
demonstrated improvements in processes of care such as use of angiotensin-
converting enzyme inhibitors and aspirin as well as intermediary outcomes
including glucose and lipid control (Chin et al. forthcoming).
Although many QI programs and disease management programs have
been found to improve chronic care (Chodosh et al. 2005), the value of such
programs has been rarely assessed with cost-effectiveness analyses (CEA).
CEA is used to illustrate the economic value of new treatments, tests, and
programs and these results provide policy makers with a common metric for
comparing diverse technologies and programs. CEA of QI programs would
allow comparison of QI programs with other health care technologies and
inform resource allocation decisions. In addition, CEA results can help iden-
tify the components of chronic care that are likely to produce the largest health
benefits for patients. These analyses can help those implementing QI pro-
grams decide where to target future improvements.
We set out to evaluate the cost-effectiveness of the Diabetes HDC pro-
gram combining data from a study of the program’s effectiveness with a com-
prehensive simulation model of diabetes complications.
METHODS
The Diabetes HDC
The HDC trains HC staff to utilize the tools of rapid QI (Wagner et al. 2001)
and chronic disease management (Von Korff et al. 1997; Bodenheimer, Wag-
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ner, and Grumbach 2002a, b). HC staff members acquire skills and share best
practices at learning sessions and develop programs tailored to their centers.
The typical Diabetes HDC program has included use of diabetes flow sheets in
medical charts to remind physicians of processes of care to be completed and
patient management software provided by HRSA’s BPHC to track patients
over time. Beyond these features, the actual type and number of QI or disease
management methods that centers have employed has varied across centers,
as encouraged by rapid QI. QI program components have included commu-
nity-health center collaboration, patient-self-management support, and deliv-
ery system redesign (e.g., group visits). More detail about the HDC
intervention is described in a prior publication (Chin et al. 2004). We eval-
uated the impact of the Diabetes HDC for 17 Midwestern HCs enrolled in the
standard intensity arm of a randomized controlled trial comparing a standard
and high-intensity Diabetes HDC program. We utilized the findings for the
standard program because it was the program that was deployed nationally.
Data Sources and HDC Effect
Data on the quality of diabetes care were collected in serial cross sections in
1998, 2000, and 2002. For each year, centers were asked to identify nonpreg-
nant adult patients (18–75 years of age) with diabetes and perform chart re-
view on 80 randomly selected patients. HC staff abstracted information on
demographics, process of care, and laboratory values from medical charts.
Both crude and adjusted analyses showed that diabetes care improved
across each time interval (Chin et al. forthcoming). For this analysis, we used
processes of care and clinical outcomes from 1998 to 2002, the longest follow-
up period of any evaluation of the HDC. Baseline (1998) rates of processes of
care were estimated using mixed logistic regression (Zeger, Liang, and Albert
2004) of outcome on intercept, with HC as a random effect. Changes in rates of
performance from 1998 to 2002 were estimated using three-level hierarchical
logistic regression (Raudenbush et al. 2001; Raudenbush and Bryk 2002) of
outcome on year, with HC and year within HC as random effects, controlling
for strata (e.g., region) and patient and HC characteristics. Candidate covari-
ates were urban versus rural location, age, sex, race, insulin treatment, co-
morbidities, and complications of diabetes. The structure of the models
reflects the cross-sectional sampling of patients nested within HCs over time.
Baseline rates and changes in values of risk factor levels were obtained using
analogous mixed and hierarchical linear regression models.
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Cost-Effectiveness Analysis
We adopted the societal perspective for this analysis. We assumed that the
population of interest was HC patients with demographic and clinical char-
acteristics of those patients seen in 1998. For this population, we compared the
projected complications, quality of life, and costs of care in two hypothetical
scenarios for the base case. The first scenario was life with the risk factor levels
and processes of care as they were in 1998 at the start of Diabetes HDC. The
second scenario was life with the risk factors levels and processes of care as
they were in 2002 with the Diabetes HDC in place. These risk factor levels and
processes of care reflect the adjusted improvements in care from 1998 to 2002.
We will refer to these scenarios as the pre-HDC and HDC scenarios.
Diabetes Complication Simulation Model
We incorporated data from the program evaluation into a previously validated
model of the cost-effectiveness of intensive glucose control for type 2 diabetes
(courtesy R. Eastman) (Eastman, Javitt, Herman, Dasbach, Copley-Merriman
et al. 1997; Eastman, Javitt, Herman, Dasbach, Zbrozek et al. 1997). This
Markov Monte Carlo simulation model is framed by simultaneous progres-
sion of disease through microvascular complications, cardiovascular compli-
cations, and mortality. Within a 1-year cycle length, patients move from one
disease state to another or stay in the current disease state until death or age 95.
For each distinct model setting, the model is run 10,000 iterations. We used
Microsoft Excel 2000 (Microsoft, Seattle, WA) and @Risk 4.5.4 for Windows
(Palisades Inc., Newfield, NY) to conduct the simulations.
We revised the original model for the purposes of this analysis. Please
see the Technical Appendix for detailed description of model inputs. We
updated the transition probabilities for microvascular complications with data
from the U.K. Prospective Diabetes Study (UKPDS), conducted in type 2
diabetes patients (DCCT Research Group 1993, 1995; UKPDS Group 1998).
For the nephropathy module, we used observations from the control arm of
UKPDS for the probability of developing microalbuminuria and proteinuria
for the pre-HDC scenario. For these complications we fitted data from UK-
PDS to the survival function form used in the original NIH model, based on
Diabetes Control and Complication Trial data (DCCT Research Group 1996).
This functional form allowed us to relate the probability of a complication to
both duration of diabetes as well as glycosylated hemoglobin levels (HbA1C).
To determine the transition probabilities for the HDC scenario and lower
sugar levels, we used UKPDS again, using the form HbA1C with preHDCHbA1C with HDC
 b
with
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the b coefficient derived from the comparison of the overall results of UKPDS
for individual complications. This is the method utilized in the CDC Diabetes
Cost-Effectiveness Model (CDC Group 2002). This approach was also applied
to the neuropathy and retinopathy modules. For the neuropathy module, we
added a new health state of foot ulcer (Young et al. 1994; Gregg et al. 2004)
and incorporated an international scoring system for diabetic foot disease
(Peters and Lavery 2001). For the retinopathy module, progression beyond
background retinopathy was updated with data from the Liverpool Diabetic
Eye study (Younis et al. 2003).
A new stroke module was added to the model with the probability of
stroke based on a Framingham prediction model (Wolf et al. 1991). The
module for coronary heart disease was revised with the inclusion of coronary
heart disease Framingham prediction model (Wilson et al. 1998). We also
adopted changes made by Eastman and colleagues after the original publi-
cation that included subsequent cardiovascular event probabilities and model
structure based on the Harvard Coronary Heart Disease Policy Model (Hun-
ink et al. 1997). The race- and gender-specific background mortality rates were
updated with U.S. life table statistics from 1999 (Andersen and DeTurk 2002).
Intervention Effects
For the base case, we conservatively assumed that intensive glucose control
had a beneficial effect on the probability of microvascular events but no effect
on cardiovascular events in patients with type 2 diabetes because clinical trials
of glucose control have yet to show a definitive cardiovascular benefit (UK-
PDS Group 1998; Huang, Meigs, and Singer 2001; DCCT Research Group
2005). However, observational studies demonstrate an association between
glucose levels and cardiovascular events (Stevens et al. 2001). We utilized the
Framingham prediction models of coronary heart disease events for the base
case and evaluated the impact of this assumption by using the UKPDS risk
prediction model for coronary heart disease in sensitivity analyses (Stevens
et al. 2001). The benefits of ACE inhibitors were based on the findings from
the Heart Outcomes Prevention Evaluation (HOPE) Study (HOPE Study
Investigators 1999; Rosen et al. 2005). Aspirin was assumed to reduce the
probability of coronary heart disease (Hansson et al. 1998) but increase the
probability of gastrointestinal bleed (American Diabetes Association 2004).
We assumed that the joint effect of aspirin and an ACE inhibitor on cardio-
vascular effects was multiplicative. We did not assume any clinical benefit of
processes of care that have not been found to independently improve out-
comes (Singh, Armstrong, and Lipsky 2005).
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Outcome Values
For the base case, we used utilities for complications found in prior CEA
(Technical Appendix) (Dasbach, Fryback, and Thornbury 1992; DCCT Re-
search Group 1996; Tennval and Apelqvist 2001; CDC Group 2002; Red-
ekop et al. 2004; Rosen et al. 2005). We assumed no disutility of life with
intensified treatments in the base case but evaluated this in sensitivity analyses
(Huang et al. 2006). When multiple health states occurred, we used the min-
imum health state method (Naglie et al. 1997).
Costs
We estimated the program costs of the HDC (Year 1 $712/patient, Year 2
$600/patient, Year 3 $472/patient, and Year 4 $378/patient) based on case
studies of selected HCs in conjunction with data obtained from HRSA’s
BPHC (Huang et al. in press) (Technical Appendix). We assumed that the
costs in Year 4 were required for the remainder of the patient’s life to sustain
HDC benefits.
The costs of diabetes care were based on observed utilization of services
with a few exceptions. The frequency of physician office visits was not col-
lected, so we assumed that the average number of office visits was 3 under pre-
HDC care and 4 under HDC care based on the protocol of a trial of com-
prehensive diabetes care (Gaede et al. 2003). The general categories of
glucose-lowering therapies (insulin, insulin and oral medications, oral med-
ications, diet) were documented, but without more details regarding the use of
specific agents. We assumed that the distribution of use of different oral agents
was the same as that observed in national studies of diabetes care (Cohen et al.
2003). The dosing of oral medications was assumed to be doubled in the HDC
scenario. The dosing of insulin was assumed to be 65 units/day under both
scenarios. The actual utilization of statins was not collected, so we assumed
that the observed utilization of statins in the nation in 1998 (Grant et al. 2004)
doubled as a result of the HDC. We estimated the costs of drugs based on the
average type and frequency of drug prescriptions, dosage of medications, and
wholesale drug prices (Red Book 2004). The costs of diabetes complications
were common to both scenarios. We updated the yearly costs of all micro-
vascular (Boulware et al. 2003; Gordois et al. 2003) and cardiovascular com-
plications (Cooper et al. 1999; Cundiff 2002; Brandle et al. 2003; Nichol et al.
2003; Hlatky et al. 2004; Van Alem et al. 2004; Rosen et al. 2005) in the
original model.
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Effectiveness, Costs, and Cost-Effectiveness
We determined the expected lifetime probability of each of the major com-
plications along with differences in costs, life years, and quality-adjusted life
years (QALYs). The main outcome of interest is the incremental cost-effec-
tiveness ratio (ICER) comparing the pre-HDC and HDC scenarios. All costs
are expressed in 2004 dollars and we used a discount rate of 3 percent for both
costs and outcomes. A discount rate of 5 percent was evaluated in sensitivity
analysis.
Sensitivity Analyses
We separately assessed the impact and cost-effectiveness of improvements in
individual components of care. For these analyses, we assumed that the entire
program cost was devoted to improving each individual component of care. In
one-way sensitivity analyses, we evaluated a range of values for probabilities,
utilization rates, or costs that had significant uncertainty. The impact of dif-
ferent program costs assumptions was of particular interest. We also evaluated
the impact of possible secular trends by systematically altering the proportion
of change in each component of care attributable to baseline secular trends.
We separately evaluated the effect of future costs, including medical costs for
unrelated illnesses, nonmedical costs, and future earnings, on the overall cost-
effectiveness results (Meltzer et al. 2000). For the future cost analysis we used
the national averages for consumption and earnings for given age groups.
Because average consumption and earnings for patients in the HC population
might differ from those in the population as a whole, we also performed
sensitivity analysis around these estimates.
RESULTS
Baseline Patient Characteristics
In 1998, the mean age of patients was approximately 55 years (Table 1). The
majority of individuals were nonwhite and about two-thirds were female.
Processes of Care and Outcomes
Multiple components of care improved from 1998 to 2002 during the imple-
mentation of the diabetes HDC (Table 2). Among screening tests, annual
glycosylated hemoglobin testing (HbA1C) (71! 92 percent), lipid testing
(52! 70 percent), microalbumin assessment (15! 44 percent), eye exams
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(25! 44 percent) all improved significantly. Similarly, ACE inhibitor
(33! 55 percent), and aspirin prescribing (22! 45 percent), also increased
significantly. Mean HbA1C (8.53 percent in 1998, mean difference  0.45
percent [95 percent confidence intervals (CI)  0.72,  0.17]) and cholesterol
levels (total cholesterol 212 mg/dL in 1998, mean difference  13.5 [95 per-
cent CI  20.4,  6.7]) decreased significantly, but blood pressure levels,
which were relatively low at baseline (133/79 mmHg in 1998), did not.
Base Case Cost-Effectiveness Results
In the base case, the HDC was found to reduce the expected lifetime incidence
of intermediate and end-stage complications (Table 3). For example, for di-
abetic retinopathy, background retinopathy (56! 54 percent), proliferative
diabetic retinopathy (32! 31 percent), and blindness (17! 15 percent) were
all reduced. Similar benefits were observed for the lifetime incidence of end-
stage renal disease (18! 15 percent) and coronary artery disease (28! 24
percent). The probability of amputation and stroke did not change. The av-
erage improvement in QALYs was 0.35. The ICER of the base case was
$33,386/QALY.
Sensitivity Analysis
The individual improvements in care produced variable effects on measures
of morbidity and mortality (Table 4). Lowering glucose control levels and
Table 1: Health Center and Baseline (1998) Patient Characteristics
Age (mean, standard deviation) 54.5 (13.6)
Female (%) 67
Race/ethnicity (%)
American Indian/Alaska native 1
Asian/Pacific Islander 1
Black (non-Hispanic) 29








Peripheral vascular disease 5
Renal failure 2
Proteinuria 7
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increasing rates of associated testing led to a lower lifetime incidence of
blindness, end-stage renal disease, and amputations. The improvements in
cholesterol control led to a lower lifetime incidences of cardiovascular events.
Similarly, enhanced aspirin prescribing led to a slight decline in coronary
heart disease events. Only ACE inhibitor utilization led to benefits in both
microvascular and cardiovascular complications. The improvements in glu-
cose control and ACE inhibitor utilization produced the largest individual
increases in QALYs (0.19). The cost-effectiveness of individual improvements
of diabetes care varied (Table 4). The increase in utilization of ACE inhibitors
was clearly cost effective (ICER $23,653/QALY), while each of the other






At least one HbA1c 71 92
Lipid assessment 52 70
Microalbumin assessment 15 44
Eye exam or referral 25 44
Foot exam or referral 31 63
ACE inhibitor 33 55
Aspirin 22 45
Insulin alone (observed) 17 12
Insulin and oral therapy (observed) 12 16





between 1998 and 2002
(95% Confidence Intervals)z
HbA1c (%) 8.53 (2.14)  0.45 ( 0.72,  0.17)
Total cholesterol (mg/dl) 212 (55)  13.5 ( 20.4,  6.7)
LDL cholesterol (mg/dl) 127 (51)  19.7 (25.8,  13.6)
HDL cholesterol (mg/dl) 47 (36)  6.4 ( 16.9, 4.0)
Systolic blood pressure (mmHg) 133 (19)  1.81 ( 4.03, 0.40)
Diastolic blood pressure (mmHg) 79 (11)  0.79 ( 1.98, 0.40)
nEstimated rate from univariate mixed logistic regression that incorporates correlation due to
clustering of patients within HCs.
wEstimated from multivariate mixed logistic regression that adjusts for covariates and incorporates
correlation due to clustering of patients within HCs.
zThree-level hierarchical regression of patient-level outcomes on year, with health center and year
within health center as random effects, controlling for region (Midwest, West Central) and Di-
abetes Collaborative (I, II). Candidate covariates: urban versus rural location, age, sex, race,
insulin treatment, comorbidities, and complications of diabetes (hypertension, myocardial infarc-
tion, peripheral vascular disease, retinopathy, neuropathy, and renal failure).
HCs, health centers
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improvements were individually not cost-effective based on a $100,000/
QALY threshold. The ICERs for improvements in individual therapies were
higher than ICERs found from CEA of individual therapies based on original
clinical trial results (e.g., intensive glucose-control ICER $41,384/QALY and
intensive cholesterol-control ICER $51,889/QALY) (CDC Group 2002).






Background diabetic retinopathy (%) 56 54
Macular edema (%) 30 30
Proliferative diabetic retinopathy (%) 32 31
Blindness (%) 17 15
Microalbuminuria (%) 63 56
Proteinuria (%) 36 30
End-stage renal disease (%) 18 15
Peripheral neuropathy (%) 61 58
Foot ulcers (%) 30 29
Amputation (%) 20 20
Coronary heart disease (%) 28 24
Stroke (%) 20 20
Life years (mean) 11.68 11.98
Quality-adjusted life years (mean) 10.58 10.93
Life-time costs (mean $) 90,085 101,770








Absolute risk reduction (%)
Blindness 2 0 0 0
ESRD 1 0 3 0
Amputation 1 0 0 0
Coronary heart disease 0 1 0 2
Stroke 0 0 1 0
Cost-effectiveness results
Quality-adjusted life years (QALYs) gained (mean) 0.09 0.02 0.19 0.03
Cost difference (mean $)n 9,433 8,337 4,494 4,553
Incremental cost-effectiveness ratio ($/QALY)n 104,811 416,850 23,653 151,767
nThese individual treatment analyses assume that the entire program cost was devoted to im-
proving an individual component of diabetes care.
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Other sensitivity analyses support the overall conclusion that the HDC
program is cost-effective. We considered the effects of potential secular trend
by systematically improving processes of care in the pre-HDC scenario,
thereby decreasing the difference between the pre-HDC and HDC scenarios.
If 50 percent of the observed improvement in every component of care was a
result of secular trends, the impact of the HDC would still be cost-effective
($54,839/QALY). Even if secular trends accounted for over 75 percent of
observed improvements, the ICER would still remain below the $100,000/
QALY threshold ($93,563/QALY). An alternative approach to viewing this
sensitivity analysis is to begin with secular improvements and ask how much
more improvements would have to be in order for the program to be cost-
effective. If 50 percent of observed improvements were already present due to
secular trends, improvements with the HDC would have to be greater than 70
percent of observed improvements to generate an ICER below $100,000/
QALY and would have to be approximately 110 percent of observed im-
provements in order to achieve an ICER below $50,000/QALY. We also
tested a wide range of assumptions regarding program costs and found that the
ICER remained at $54,060/QALY even when assuming high and constant
program costs ($1,000/patient/year). The increased costs of the HDC scenario
compared with the pre-HDC scenario are largely related to the costs of routine
diabetes care. When using the UKPDS risk engine in place of the Framingham
risk equation for coronary heart disease, the difference in lifetime probability
of coronary heart disease increased (34 versus 29 percent) and the ICER
decreased to $26,276/QALY. When accounting for future costs with base case
assumptions, the overall ICER decreased to $29,437/QALY. These results did
not change significantly with additional sensitivity analyses regarding as-
sumptions such as earnings or consumptions.
DISCUSSION
During the first 4 years of the Diabetes HDC program, we observed im-
provements in multiple dimensions of diabetes care in community healthy
center patients; this study joins a growing body of literature illustrating the
potential benefits of QI programs. Although multiple QI programs have been
found to produce improvements of similar or greater magnitude (Chodosh
et al. 2005), the economic value of these programs is generally unknown
because CEA of QI programs, designed to improve the delivery of care, have
been rarely conducted (Mason et al. 2001). To our knowledge, this is one of the
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first studies to examine the cost-effectiveness of QI of diabetes care. It is also one
of the first studies to examine the clinical and economic impact of compre-
hensive diabetes care (CDC Group 2002). Given the ubiquitous nature of dis-
ease management programs and QI programs, the lessons learned from this
evaluation of the HDC program can provide important insight for policy mak-
ers allocating health care dollars and for those who implement QI programs.
Based on improvements in diabetes care observed during the first 4
years of the HDC, we find that the Diabetes HDC program is cost-effective at a
level comparable with that of other health care technologies (Coffield et al.
2001). This basic knowledge is valuable for policy makers who are deciding
whether to continue or expand QI programs. Our results provide additional
lessons for ongoing QI programs regarding how to maximize their effective-
ness and cost-effectiveness (Casalino 2005). First, our results illustrate how the
effectiveness of improving individual elements of diabetes care can vary
widely. The individual improvements that produced the largest health benefits
were the lowering of glucose levels and the increase in ACE inhibitor utili-
zation. ACE inhibitor utilization was clearly the most cost-effective area of
improvement in care. Our results illustrate that improving diabetes care com-
prehensively remains the ideal, and that it is crucial not to neglect components
of care such as ACE inhibitor prescribing or blood pressure control that have
wide ranging health effects and are relatively cost-effective (CDC Group 2002;
Vijan and Hayward 2003; Rosen et al. 2005). Second, our sensitivity analysis
on program costs show that while the QI program costs certainly influenced
results, they were not the major determinants of the overall cost-effectiveness
of the program. Our case studies actually indicate that QI program costs are
lower than the $1,000/patient/year we used in sensitivity analyses and that
program costs typically decline over time as centers gain experience in im-
plementing QI initiatives. Our program cost assumptions were also conser-
vative in that we assumed that secular improvements in diabetes care did not
require any additional resource use.
Establishing the societal cost-effectiveness of the Diabetes HDC pro-
gram is valuable; however, this knowledge does not ensure that the benefits or
cost-effectiveness of this program will be realized over the long term. Our
study assumed a traditional societal perspective but no one entity represents
society in our fractured health care system. Individual organizations make the
decisions to support QI programs or sustain their effects. The costs of the HDC
program itself are borne by HCs and HRSA’s BPHC. We have found that
HCs routinely experience financial losses while operating the HDC program,
raising concerns about its sustainability (Huang et al. in press). More impor-
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tantly, the costs of routine diabetes care of HC patients are borne by HRSA’s
BPHC and Medicaid. Without such programs, HC patients may not be able to
receive regular health care, obtain medications regularly, and maintain op-
timal control of risk factors. Therefore, the basic provision of chronic care for
vulnerable patients is a crucial ingredient for sustaining the health care benefits
of the HDC program and, in turn, will ultimately determine the cost-effec-
tiveness of this QI program.
The chief limitation of our study is that we based the effect of the HDC
program on changes in care over time, which raises the question, to what
extent are secular trends driving improvement. Assessing changes over time is
a very common approach to outcome assessment for most QI programs. The
national HDC program was intended to be delivered to as many vulnerable
patients as possible and a randomized controlled trial of the basic program was
not considered. To address the possible effect of secular trends, we conducted
sensitivity analyses and found that secular trends in diabetes care would have
to account for the majority of improvements in order to make the HDC cost-
ineffective. In addition, comparisons with studies of national trends lead us to
believe that a majority of the changes observed in these HCs are distinct from
general secular trends. For example, a contemporaneous study of diabetes
care using NHANES data found improvements in cholesterol levels and sys-
tolic blood pressure but no improvements in mean glucose levels (Saydah,
Fradkin, and Cowie 2004). In our study, improvements occurred in HbA1c
and cholesterol levels but not for blood pressure. In addition, the increases in
ACE inhibitor and aspirin utilization observed in our study are larger than
those observed in national studies (e.g., aspirin 40 percent national increase
versus 105 percent, ACE inhibitor 40 versus 66 percent) (Nau, Garber, and
Herman 2004; Stafford, Monti, and Ma 2005). When considering the possible
effects of secular trends, it is also important to note that HCs are systematically
different from other care settings by virtue of the large proportion of uninsured
and Medicaid patients that they serve and that these patients may actually
present greater challenges to the routine delivery of chronic care compared
with other health care systems (Kerr et al. 2004; Pham et al. 2005). We also
know from prior study of diabetes patients in HCs that the population is
relatively stable with 72 percent of patients remaining from 1 year to the next
(Chin et al. 2001), a fact that helps to lessen concerns regarding the effects of
secular trends.
These results should be considered in light of this study’s other limita-
tions. The main results of our study come from 17 Midwestern HCs and
their experiences may not be representative of centers across the nation. In
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addition, the cost-effectiveness of improving diabetes care in HCs cannot be
assumed to be the same for other clinical settings and patient populations. HC
patients are younger and have greater minority representation than the gen-
eral population. Given both of these characteristics, these patients are more
likely to benefit from improvements in diabetes care during the course of their
lifetimes. At the same time, this population presents unique challenges to care
management. To what extent these factors shift the balance of the cost-effec-
tiveness of QI is unclear and deserves further study. Apart from the unique
features of HC patients, our results are also based on a simulation model of
diabetes-related complications that is based upon multiple assumptions re-
garding the nature of diabetes. However, simulation models are the only
feasible way of estimating the long-term impact of diabetes-related treatments.
We also had some incomplete information regarding patients and their care;
for example, we did not know the exact utilization of statins over time. Where
data were missing, we made conservative assumptions. In addition, our anal-
ysis underestimates the overall health impact and social value of the HDC
program. We focus on improvements in diabetes care when in fact the HDC is
intended to improve care across multiple conditions.
Despite these limitations, this analysis provides valuable lessons regard-
ing the value of improving chronic disease management. The initial impact of
the HDC on diabetes care has led to improvements across multiple compo-
nents of diabetes care that are, in aggregate, substantial. If these benefits are
sustained or enhanced over the lifetime of patients, the HDC program will be
cost-effective for society. What resources will be required to accomplish this in
HCs is an important area of policy analysis and investigation. Our results also
indicate that future QI efforts may be particularly valuable if they lead to
improved delivery of treatments that produce benefits in multiple areas of
health.
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